3 Results for "

multinucleation

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "multinucleation" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-124757
CAS No.: 932359-76-7
Purity:  99.87%
Target:  

Proteasome Mitosis

Research Areas:  

Cancer

FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers .
loading...
    loading...
Cat. No.: HY-151424
CAS No.: 2319587-80-7
Purity:  99.74%
Target:  

Proteasome Mitosis

Research Areas:  

Cancer

Vimentin-IN-1 is a FiVe1 derivative, an orally active and selective anticancer agent. FiVe1 binds type III intermediate filament protein vimentin (VIM), to induce hyperphosphorylation of Ser56, resulting selective disruption of mitosis and multinucleation in transformed VIM-expressing mesenchymal cancer cells. Vimentin-IN-1 shows better oral bioavailability and pharmacokinetic profiles than FiVe1 .
loading...
    loading...
Cat. No.: HY-169183
Target:  

Myosin

Research Areas:  

Others

Myokinasib-II is a MLCK1 inhibitor with an IC50 of 4.4 μM. Myokinasib-II induces cell cortex softening, impairs cell migration capacity, induces multinucleation, reduces cell stiffness, alters membrane tether dynamics, decreases actomyosin tension and changes nuclear morphology. Myokinasib-II is a MLCK1 chemical biology probe with a unique structure that does not depolymerize tubulin and maintains cell viability even under high-concentration treatment in fibroblasts .
loading...
    loading...